Speech-Induced Suppression for Delayed Auditory Feedback in Adults Who Do and Do Not Stutter.
Akira Toyomura, Daiki Miyashiro, Shinya Kuriki...
https://pubmed.ncbi.nlm.nih.gov/32390816Actively Recruiting
Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07215884
Dopamine and Sensorimotor Function in Stuttering
Led by University of California, San Francisco · Updated on 2025-10-14
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the effects of aripiprazole, a drug that affects dopamine, on adults who stutter. Stuttering is a speech disorder that affects fluency, and this study aims to better understand the sensorimotor pathways involved in stuttering and explore possible treatments. The study focuses on how fluency may improve through auditory feedback changes or drugs that regulate dopamine uptake. Participants will receive a single oral dose of 10 mg aripiprazole or a placebo. The study is randomized and triple-blinded, meaning neither participants nor administrators know which treatment is given. This dose is investigational for stuttering and differs from typical uses of aripiprazole, which is approved for other mental health conditions. During the study, participants will be assessed 3 to 4 hours after taking the dose for changes in speech-related brain activity and auditory processing, such as pre-speech auditory modulation and feedback alterations. Researchers will measure these outcomes to understand how aripiprazole affects speech fluency and sensorimotor function. The study is sponsored by the University of California, San Francisco and includes healthy adults aged 18 to 65 who stutter.
CONDITIONS
Brief Title
Dopamine and Sensorimotor Function in Stuttering
Who Can Participate
Age: 18Years - 65Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Native speakers of American English
- Adults aged 18 to 65 years
- Presence of stuttering with onset before age 6 years
- Normal hearing
- Healthy adults without hearing or language difficulties
You will not qualify if you...
- Speech-language-hearing difficulties other than stuttering
- Neurological or psychological problems
- Current use of medications affecting the dopaminergic system or benzodiazepines
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 3 to 4 hours after each dose
Participants receive a single dose of aripiprazole or placebo, and effects on speech and sensorimotor function are assessed.
1 visit per dose (in-person)
Trial Site Locations
Total: 1 location
1
Biomagentic Imaging Lab
San Francisco, California, United States, 94143
Actively Recruiting
Loading map...
Research Team
N
Natalie Brunwin, MS
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Speech-induced suppression of evoked auditory fields in children who stutter.
Deryk S Beal, Maher A Quraan, Douglas O Cheyne...
https://pubmed.ncbi.nlm.nih.gov/21095231Auditory evoked fields to vocalization during passive listening and active generation in adults who stutter.
Deryk S Beal, Douglas O Cheyne, Vincent L Gracco...
https://pubmed.ncbi.nlm.nih.gov/20452437Stuttering adults' lack of pre-speech auditory modulation normalizes when speaking with delayed auditory feedback.
Ayoub Daliri, Ludo Max
https://pubmed.ncbi.nlm.nih.gov/29169049Modulation of auditory processing during speech movement planning is limited in adults who stutter.
Ayoub Daliri, Ludo Max
https://pubmed.ncbi.nlm.nih.gov/25796060Electrophysiological evidence for a general auditory prediction deficit in adults who stutter.
Ayoub Daliri, Ludo Max
https://pubmed.ncbi.nlm.nih.gov/26335995No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
Chul-Hyun Park, Tae-Won Park, Jong-Chul Yang...
https://pubmed.ncbi.nlm.nih.gov/22241281Case report of aripiprazole for persistent developmental stuttering.
Nancy L Tran, Gerald A Maguire, David L Franklin...
https://pubmed.ncbi.nlm.nih.gov/18626285Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Study.
Byoung-Uk Kim, Hyo-Won Kim, Eun Jin Park...
https://pubmed.ncbi.nlm.nih.gov/36112116The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis.
Gerald A Maguire, Diem L Nguyen, Kevin C Simonson...
https://pubmed.ncbi.nlm.nih.gov/32292321